Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Aug 1999

Kooby D A, Carew J F, Halterman M W, Mack J E, Bertino J R, Blumgart L H, Federoff H J, Fong Y

Abstract excerpt

G207 is a multi-mutated, replication-competent type-1 herpes simplex virus designed to target, infect, and lyse neurological tumors. This study examines the feasibility of using G207 in the treatment of human colorectal cancer and defines the biological determinants of its antitumor efficacy. This virus was tested on five human colorectal cancer cell lines in vitro to determine efficacy of infection and tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Death
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Herpesvirus 1, Human

Share to Liver Neoplasms

Share to Neoplasm Transplantation

Share to Rats, Nude

Share to Virus Replication

Source

Identifiers

PMID: 10428757
DOI: 10.1096/fasebj.13.11.1325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).PMID 10428757Read ↗

Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.Semantic proximity Read ↗

An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.Semantic proximity Read ↗

Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.Semantic proximity Read ↗

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.Semantic proximity Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

Oncolytic virus therapy using genetically engineered herpes simplex virusesSemantic proximity Read ↗

A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancerSemantic proximity Read ↗

Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.Semantic proximity Read ↗

Cancer Gene Therapy Using a Replication-Competent Herpes Simplex Virus Type 1 VectorSemantic proximity Read ↗

Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBMSemantic proximity Read ↗

Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.Semantic proximity Read ↗

Expanded spectrum of viral therapy in the treatment of nervous system tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.